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Clindamycin-rifampin combination therapy
for staphylococcal periprosthetic joint
infections: a retrospective observational
study
Borg Leijtens1* , Joris B. W. Elbers1, Patrick D. Sturm2, Bart Jan Kullberg3 and Berend W. Schreurs1
Abstract
Background: Staphylococcal species account for more than 50% of periprosthetic joint infections (PJI) and antimicrobial
therapy with rifampin-based combination regimens has been shown effective. The present study evaluates the safety and
efficacy of clindamycin in combination with rifampin for the management of staphylococcal PJI.
Methods: In this retrospective cohort study, patients were included who received clindamycin-rifampin combination
therapy to treat a periprosthetic hip or knee infection by Staphylococcus aureus or coagulase-negative staphylococci.
Patients were treated according to a standardized treatment algorithm and followed for a median of 54 months.
Of the 36 patients with periprosthetic staphylococcal infections, 31 had an infection of the hip, and five had an infection
of the knee. Eighteen patients underwent debridement and retention of the implant (DAIR) for an early infection, the other
18 patients underwent revision of loose components in presumed aseptic loosening with unexpected positive cultures.
Results: In this study, we report a success rate of 86%, with five recurrent/persistent PJI in 36 treated patients. Cure rate
was 78% (14/18) in the DAIR patients and 94% (17/18) in the revision group. Five patients (14%) discontinued clindamycin-
rifampin due to side effects. Of the 31 patients completing the clindamycin-rifampin regimen 29 patients
(94%) were cured.
Conclusion: Combined therapy with clindamycin and rifampin is a safe, well tolerated and effective regimen for the
treatment of staphylococcal periprosthetic infection.
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Background
Periprosthetic joint infections (PJI) cause significant
morbidity and a considerable claim on the health care
resource utilization. Implant-associated infections are
typically caused by microorganisms that adhere to the
device surface and produce microbial biofilms. Staphylo-
cocci account for more than 50% of the periprosthetic
joint infections [1]. The treatment is challenging, as the
organisms in the biofilm are protected from antimicro-
bial agents and host responses, and have greater resist-
ance to antimicrobial killing [2, 3]. Rifampin-based
combination therapy regimens have been shown effect-
ive to eradicate staphylococcal biofims and cure PJI [4].
In the widely-used algorithm proposed by Zimmerli et
al. [3] and the IDSA (Infectious Disease Society of
America) guidelines [5], rifampin is combined with quin-
olones, and cure rates of 70-100% have been reported.
Although other agents, e.g., betalactams, glycopeptides,
minocycline, cotrimoxazole, linezolid, daptomycin, or
fusidic acid have been investigated in combination with
rifampin, their efficacy is in general inferior or data are
anecdotal [4–7]. Clindamycin has been well established
as antistaphylococcal therapy, but very few clinical data
are available about its use in combination with rifampin
for PJI. Therefore, clindamycin has not yet been recom-
mended as an alternative to combine with rifampin to
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treat PJI in the IDSA guidelines [5]. Clindamycin has
been shown to be effective in treatment of osteomyelitis
[8], has excellent bioavailability, high levels of penetra-
tion into synovial fluid and bone [9, 10], inhibits biofilm
formation and bacterial adherence and is well tolerated
[11, 12]. In vitro, clindamycin prevents the emergence of
rifampin resistance, and the combination displayed syn-
ergetic or additive bactericidal activity, as well as favor-
able cure rates in animal models [13–18]. To date, only
2 case series have reported on the efficacy of an oral
clindamycin-rifampin combination therapy regimen for
staphylococcal PJI in adults, with a success rate of 70%
in 7 cases and 100% in 6 cases [6, 19].
In the present study, we evaluated the efficacy and safety
of a clindamycin-rifampin combination therapy regimen
for the management of PJI caused by Staphylococcus
species.
Methods
Patients
For this retrospective cohort study, patients who re-
ceived complete treatment for PJI of the hip (118) or
knee (36) in our hospital between January 2004 and June
2010 were eligible. Inclusion criteria were PJI due to S.
aureus or coagulase-negative staphylococci (CoNS). The
isolated staphylococci had to be susceptible in vitro to
both clindamycin and rifampin which was determined
by automated susceptibility testing using the BD
Phoenix™ (BD Diagnostics, Sparks, MD, USA).
Diagnosis
PJI was diagnosed according to the MSIS (Musculoskel-
etal infection society) criteria [20]; Presence of 1-2 major
criteria and/or three minor criteria. Major criteria are: 1)
two positive periprosthetic cultures with phenotypically
identical organisms 2) A sinus tract communicating with
the joint. Minor Criteria are: 1) Elevated serum C-react-
ive protein AND erythrocyte sedimentation rate 2) Ele-
vated synovial fluid white blood cell count OR ++change
on leukocyte esterase test strip 3) Elevated synovial fluid
polymorphonuclear neutrophil percentage 4) Positive
histological analysis of periprosthetic tissue 5) A single
positive culture. In case of postoperative events, newly
isolated microorganisms were typed by standard mo-
lecular techniques if necessary.
Management
Management of PJI was based on the treatment algo-
rithm by Zimmerli et al. [3] and the IDSA Guidelines
[5], performed by a multidisciplinary team consisting of
an orthopedic surgeon, a microbiologist and an infec-
tious diseases specialist.
Debridement
DAIR was applied for (a) early postoperative or acute
haematogenous infection, with (b) duration of symptoms
<3 weeks, (c) a stable implant and (d) if soft tissue was
in good condition. The wound was re-opened, deep cul-
tures were taken, debridement was performed and pulse
lavage was used with at least 3 l of NaCl 0.9% solution.
Gentamicin beads were inserted based on the surgeon’s
decision and removed after 2 weeks. No change of mo-
bile parts was performed during surgery.
Revision
This group consisted of patients who underwent a revi-
sion of (a part of ) the prosthesis for presumed aseptic
loosening in the absence of positive MSIS criteria pre-
operatively. In these included cases, two or more peri-
operative taken cultures showed bacterial growth and
retrospectively proved a prosthetic joint infection ac-
cording to the MSIS criteria. At the revision, debride-
ment was performed and pulse-lavage was used with at
least three litres of NaCl 0.9% solution. In case of puru-
lence at the implant site, complete revision was per-
formed. Otherwise, only loose parts of the implant were
revised and stable parts were let in situ. So retrospect-
ively, these patients underwent a one-stage revision of
all loose parts of the implant for septic loosening. If indi-
cated, bone defects were reconstructed with impaction
bone grafting [21]. A cemented prosthesis was inserted
using Simplex® bone cement with 500 mg erythromycin
and 3.000.000EH colistin (Stryker, Newbury, UK) [22, 23].
Antimicrobial treatment
Surgical prophylaxis (cefazolin 2 g intravenously) was
administered after deep tissue cultures were taken. Post-
surgery, initial intravenous therapy was continued for
2 weeks with a betalactam antibiotic, clindamycin or tei-
coplanin, based on previous cultures if present. Antibi-
otics were switched to oral withtin 2 weeks. Oral
antibiotic regimen consisted of: clindamycin (600 mili-
grams three times daily) and rifampin (450 miligrams
twice daily) for a minimum of 3 months, once the isolate
had been identified and found susceptible to both drugs.
Follow-up
Patients were clinically and radiographically evaluated at
the outpatient clinic at 6 weeks, 3, 6 months, and then
yearly. Follow-up was continued until April 2015 with a
median of 54 months (range 1-120).
Definitions
Cure: (a) no clinical, radiological or laboratory signs of
infection at the latest follow-up, with a minimum of
2 years after re-implantation, (b) proven negative peri-
operative cultures in case of reoperation for other
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reasons than infection or (c) positive cultures yielding a
different microorganism after an uneventful follow-up of
at least 2 years. Failure (persistence/recurrence of infec-
tion): (a) persistent or recurrent signs of infection in the
first 2 years after debridement or one-stage revision, re-
gardless the microorganism in newly obtained cultures
or (b) isolation of the same microorganism as found at
the initial treatment at any reoperation on the affected
side during follow-up.
Statistical analysis
Graphpad Prism© version 11.0 was used for creation of
the Kaplan-Meier curves. Data were analysed according
to the intention-to-treat principle. No p-values were cal-
culated since goal of this study was to evaluate the out-
come of this treatment protocol and not to compare the
outcome of DAIR versus one-stage revision.
Results
Study population
Between January 2004 and June 2010, 154 patients re-
ceived treatment for PJI of the hip (118 patients) or knee
(36 patients). PJI of the hip was treated with DAIR (38
patients), one-stage revision (31), two-stage revision (33)
or prosthesis removal without prosthesis replacement
(16). Patients with total knee arthroplasty infection were
treated with DAIR (18 patients), one-stage revision (2),
two-stage revision (13), arthrodesis (1) or amputation
(2). Of the 89 patients treated with DAIR or one-stage
revision, 51 patients had a staphylococcal PJI. Fifteen of
those patients were excluded due to the following rea-
sons: potential rifampin drug interaction (1); possibility
of iMLSb phenotype resistance (1) [24]; clindamycin (5)
or rifampin (5) resistance (in 9 out of these 10 patients,
the microorganism was resistant to quinolones as well).
Three patients were excluded based on protocol violation.
A total of 36 patients (23%) were treated with the
clindamycin-rifampin combination therapy after DAIR
(18 patients) or revision (18 patients). Demographic
characteristics of all patients are shown in Table 1. Dur-
ation of symptoms before surgery was <3 weeks in all
cases in the debridement group. There were six patients
with an acute haematogenous PJI in the DAIR group.
Duration of symptoms was >3 weeks in all patients in
the revision group (4-79 weeks). Characteristics of all PJI
are presented in Table 2.
Surgical treatment
In the debridement group, gentamicin beads were
inserted in ten cases (56%) and removed at a second de-
bridement. Median duration of surgery was 35 min
(range, 18-94). In the revision group, complete revisions
was performed in six cases and partial revisions in 12
cases (eight acetabulair and four femoral), with a median
duration of surgery of 171 min (90-290). In 15 patients
(83%), bone defects were reconstructed with impaction
bone grafting (Table 3).
Antimicrobial treatment
Surgical prophylaxis (cefazolin 2 g intravenously) was
administered in all patients. Table 3 summarizes the
antibiotic regimen in our patient group. The minimum
duration of oral clindamycin-rifampin treatment was
70 days in the debridement group and 66 days in the re-
vision group, both after initial intravenous therapy.
Side effects and treatment discontinuation
Five of the 36 patients (14%) discontinued clindamycin
due to side effects after 3-41 days (Table 3). In the
Table 1 Patients with periprosthetic Staphylococcus infection
receiving clindamycin-rifampin combination therapy
Debridement
and retention
Revision
n (%) n (%)
Number of patients 18 18
Age, years; median (range) 71 (39 – 89) 58 (30 – 87)
BMIa, kg/m2; median (range) 26 (20 – 32) 25 (19 – 35)
Gender, male 12 13
Prosthesis site
Hip 13 18
Knee 5 0
Indication for prosthesis
Primary arthrosis 5 3
Secondary arthrosis
Childhood hip disease 1 4
Post traumatic 3 2
Osteonecrosis 1 1
Rheumatoid arthritis 1 0
Hemophilia 1 0
Revision arthroplasty 5 6
Unknown 0 2
Femoral neck fracture 1 0
Risk factors for PJIb / comorbidity
Previous hip/knee surgery before
primary THA/TKA
10 10
Immune suppression 1 2
Previous PJI 1 2
Diabetes Mellitus 2 2
Obesity (BMIa > 30 kg/m2) 1 3
ASAc score; median (range) 2 (1 – 3) 2 (1 – 3)
aBMI, Body Mass Index
bPJI, Periprosthetic Joint Infection
cASA, American Society of Anesthesiologists; THA, total hip arthroplasty; TKA,
total knee arthroplasty
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debridement group, one patient switched to levofloxacin
because of fatigue and loss of appetite, one patient to
flucloxacillin because of rash and one patient to cipro-
floxacin due to an allergic reaction to clindamycin. In
the revision group, one patient switched to teicoplanin
and one patient to ciprofloxacin, both because of diar-
rhea, without demonstration of Clostridium difficile
toxin. The latter patient experienced the same severity
of diarrhea on ciprofloxacin as on clindamycin, but was
able to complete antibiotic treatment. All five patients
continued with rifampin treatment.
Dose reduction of rifampin (to 300 mg bid) was
applied in six patients (17%), due to side effects (three
patients) and co morbidities (three patients) (Table 3).
All of these patients were treated successfully.
Treament outcome
As shown in Table 3, 86% of the patients (31 out of 36
patients) were treated successfully. The Kaplan-Meier
survival curve of time to treatment failure is shown in
Fig. 1. In patients completing the clindamycin-
rifampin regimen, cure rate was even higher; 29 out
of 31 patients (94%).
Characteristics of treatment failures are shown in
Table 4. In three of the five failures clindamycin was
switched to an alternative antibiotic due to side effects;
all after DAIR. The two other failures had a recurrent
PJI despite a complete clindamycin-rifampin treatment;
one in the DAIR group, the other in the revision group.
Three patients died due to non-orthopedic causes
without any signs of infection after 36-84 months of
follow-up. Four patients underwent a re-operation of the
affected side. In two of these patients cultures at reoper-
ation were negative. One patient experienced a peripros-
thetic fracture 4.5 years after one-stage revision for S.
aureus infection. At re-operation two different strains of
CoNS were isolated, both susceptible to clindamycin and
rifampin. In another case, late prosthetic infection oc-
curred at 54 months after complete clinical cure of PJI
with S. epidermidis. A Girdlestone procedure was per-
formed with collection of 12 cultures from 4 different
areas. Again S. epidermidis was cultured that was now
clindamycin and rifampin resistant. The stored isolates
of the initial infection and the infection after 54 months
were unrelated as established by fingerprinting using
Raman spectroscopy, SpectraCell RA® method (River
Diagnostics, Madison, WI) [25].
Discussion
In the present report, we describe 36 patients with
culture-confirmed staphylococcal PJI treated with the
combination of clindamycin and rifampin, leading to a
probability of cured infection of 86% after >4 years of
follow-up and 94% in patients able to complete
clindamycin-rifampin therapy. These results are compar-
able to those reported in previous research combining
rifampin with different antibiotics. Zimmerli et al.
describe a 100% success rate after debridement and
ciprofloxacin-rifampin combination therapy with a me-
dian follow-up of 35 months in 18 patients of whom 12
completed the treatment regimen [26]. In four patients
(22%) rifampin dose was reduced and two patients (11%)
discontinued rifampin or ciprofloxacin. Among these six
drop outs there were two failures. Another retrospective
cohort study presents a 77% infection free survival after
24 months in 43 methicillin resistant staphylococcal PJI
treated with rifampin and fucidic acid after DAIR [27]. A
large multicenter cohort study presents a 55% success
rate in 328 PJI treated with rifampin plus any other anti-
biotic after DAIR [28].
The side effects of clindamycin-rifampin combination
therapy were limited in our study. Treatment was dis-
continued in 5/36 (14%) patients, due to side effects.
This adverse event rate is similar to that reported for
other regimens, such as 14% (diarrhea) during rifampin-
levofloxacin and 16% (nephrotoxity and diarrhea) during
levofloxacin alone [29]. In the study where rifampin and
fucidic acid were combined, 3 patients (7%) experienced
side effects.
Our treatment protocol slightly deviated from the ori-
ginal algorithm published by Zimmerli et al. [3]. First,
not all patients were treated with 2 weeks of intravenous
antibiotics initially. However, due to its excellent bio-
availability, clindamycin seems appropriate for early oral
therapy resulting in reduction of hospital stay and costs.
Second, some patients with PJIs of the knee were treated
Table 2 Characteristics of periprosthetic infection
Debridement
and retention
(n)
Revision
(n)
Number of patients 18 18
Manifestation of infection
Early (≤ 3 months) 12 3
Delayed (3-24 months) 2 2
Late (≥ 24 months) 4 13
Age of implant, weeks; median (range) 7 (1 – 442) 263 (29 - 862)
Referred from another hospital 0 9
Perioperative cultures
Methicillin-susceptible Staphylococcus
aureus
11 2
Methicillin-resistant Staphylococcus
aureus
1 0
Coagulase-negative staphylococci 5 14
Polymicrobial 1 2
Number of positive cultures per patient;
median (range)
3 (1 – 7) 6 (2 – 9)
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for a limited period of time (17-34 weeks), whereas
guidelines recommend antibiotic treatment for 6 months
in case of periprosthetic knee infection [3]. The evidence
supporting a long duration of treatment is limited [30],
and 3 months of treatment may be sufficient similar to
periprosthetic hip infection [31, 32]. Third, the optimal
dose of rifampin is unknown, and results from other
studies suggest that rifampin 600 mg/24 h is as effective
as 900 mg/24 h [6, 33]. Therefore, in 6 patients, rifampin
dose reduction to 600 mg/24 h was administered due to
side effects, drug interaction or co-morbidity. All were
treated successfully. This dose reduction regimen is sup-
ported by recently published data on rifampin dosage
and frequency in PJI [33].
This study has several limitations. First, patients were
not randomized to receive clindamycin-rifampin or a
comparator regimen. However, the high success rate
suggests that the present regimen may be as effective as
quinolone-rifampin combination therapy, warranting a
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Fig. 1 Probability of cure. Kaplan-Meier survival curves of the total
group of 36 patients. Tick marks indicate patients censored due to
loss of follow-up or infection-unrelated events. Dotted lines indicate
confidence intervals
Table 3 Characteristics of surgical and antimicrobial therapy
Debridement and retention
n = 18
n
Revision
n = 18
n
Total
n = 36
n
Surgery
Duration of surgery, minutes; median (range) 34 (18-94) 1 71 (90-290) 91 (18-290)
Gentamicin beads used 9 (53) -
Bone impaction grafting - 15 (83)
Complete / partial revision - 6 (33) / 12 (67)
Antimicrobial therapy
Prior intravenous antibiotics 12 9 21
Duration of iv therapy, days; median (range) 11 (2 - 56) 12 (2 - 15) 11 (2-56)
Duration of iv + oral antibiotic therapy, days; med (range) 101 (31 – 239) 92 (80 – 139) 98 (31-239)
< 90 days 3 2 5
Hip PJIa, median (range) 98 (31-146) 92 (80-139) 95 (31-146)
Knee PJI, median (range) 182 (117-239) -
Rifampin dose reduction (300 mg twice daily) 3 3 6
Clindamycin-rifampin discontinuation 3 2 5
Due to:
Comorbidities 2 1 3
Side effects
Allergy/Rash 2 1 3
Nausea 2 1 3
Diarrhea 0 2 2
Treatment outcomes
Failures 4 1 5
Successfully treated 14 (78%) 17 (94%) 31 (86%)
Patients completed clindamycin-rifampin regimen 15 16 31
➜ Successfully treated 14 (93%) 15 (94%) 29 (94%)
aPJI, Periprosthetic Joint Infection
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prospective, randomized controlled trial. A second limi-
tation is the limited number of patients in the present
study cohort. Also, we regret the heterogeneity of the
cohort; In the DAIR group, gentamicin beads were
inserted based on the surgeon’s decision and removed
after 2 weeks. In the revision group, complete revisions
were performed in six cases and partial revisions in 12
cases. Furthermore, 15 of the 18 cases had a significant
bone defect which was reconstructed with impaction
bone grafting.
While performing this study, two articles on the
pharmacokinetics of the clindamycin-rifampin combin-
ation regimen were published [34, 35]. Bernard et al. and
Cruris et al. reported a dramatic reduction of clindamy-
cin serum concentration in patients receiving clindamy-
cin with rifampin compared to patients receiving
clindamycin without rifampin. This reduction could be
explained by the induction of cytochrome P450 by
rifampin. Clindamycin is metabolized through CYP3A4,
a member of the cytochrome P450 system. Despite their
low numbers of patients these studies found a significant
decline of serum concentration levels of clindamycin,
below therapeutic range. However, Bernard et al. report
a 82% success rate in 11 patients receiving clindamycin
with rifampin for a staphylococcal osteo-articular infec-
tion. Cruris et al. report a 100% success rate in 7 patients
receiving clindamycin with rifampin. Zeller et al. ana-
lysed 24 patients receiving continuous iv clindamycin
therapy combined with rifampin. Serum clindamycin
concentrations declined after rifampin administration
but not below therapeutic concentration [12]. Specific
success rate of this group is not documented.
We emphasise that pharmacokinetics and optimal
serum concentration levels of this combination regimen
needs to be investigated. Another recently published art-
icle describes the termination of a prospective study due
to a dramatic decline in fusidic acid plasma concentra-
tion when used in combination with rifampin [36]. The
likely explanation for this decline would again be the in-
duction of CYP3A4 by rifampin.
The strengths of the present study are the inclusion of
culture-proven PJIs of the hip and knee only, excluding
other implanted devices. In addition, we report high suc-
cess rates in partial one-stage revisions in preoperatively
considered aseptic loosening which turned out to be
septic. This indicates that this antibiotic combination
therapy is capable of eradicating a PJI without removal
of all devices. Furthermore, during the entire study
period, a standardized multidisciplinary approach ac-
cording to international treatment algorithms was used.
Conclusion
Clindamycin-rifampin combination therapy results in
a high success rate in the treatment staphylococcal
PJI. The present findings warrant a randomized con-
trolled trial to assess whether this combination regi-
men is a welcome addition to our arsenal against
staphylococcal PJI.
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